Oxygen-carrying nanoplatform to reprogram tumor immunosuppressive microenvironment and enhance photothermal-immunotherapy
Source abstract
Abstract
Immunotherapy shows great promise on treating tumors. However, insufficient antigen exposure and immunosuppressive tumor microenvironment (TME) caused by hypoxia impose a serial of constraints on the therapeutic efficacy. In this study, we developed an oxygen-carrying nanoplatform loaded with perfluorooctyl bromide (PFOB, a second-generation of perfluorocarbon-based blood substitute), IR780 (a photosensitizer) and imiquimod (R837, an immune adjuvant) to reprogram immunosuppressive TME and reinforce photothermal-immunotherapy. The obtained oxygen-carrying nanoplatforms (abbreviated as [email protected]/PFOB) show highly efficient oxygen release behavior and excellent hyperthermia performance upon laser irradiation, thus achieving the attenuation of the inherent tumor hypoxia and the exposure of tumor associated antigens in situ, and transforming the immunosuppressive TME to an immunosupportive one. We found that the photothermal therapy of [email protected]/PFOB together with anti-programmed cell death protein-1 (anti-PD-1) would elicit a robust antitumor immunity by increasing the tumor-infiltrating frequencies of cytotoxic CD8+ T cells and tumoricidal M1-phenotype macrophages, while reducing immunosuppressive M2-phenotype macrophages and regulatory T cells (Tregs). This study presents these oxygen-carrying [email protected]/PFOB nanoplatforms are potent in removing some negative impacts of immunosuppressive TME caused by hypoxia, and suppressing tumor growth by initiating antitumor immune responses, especially in combination with anti-PD-1 immunotherapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Cancer, Hypoxia, and Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (54)
Show source-provided references
1. Neoantigens in cancer immunotherapy10.1126/science.aaa4971 ↗
2. Engineered cellular immunotherapies in cancer and beyond10.1038/s41591-022-01765-8 ↗
3. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications, Cell10.1038/s41423-020-0488-6 ↗
4. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade10.1016/j.cell.2021.09.020 ↗
5. A paradigm shift in cancer immunotherapy: from enhancement to normalization10.1016/j.cell.2018.09.035 ↗
6. Association between estimated cumulative vaccine antigen exposure through the first 23 months of life and non-vaccine-targeted infections from 24 through 47 months of age10.1001/jama.2018.0708 ↗
7. Therapeutic cancer vaccines10.1038/s41568-021-00346-0 ↗
8. Beyond immune checkpoint blockade: emerging immunological strategies
9. A self-amplifying nanodrug to manipulate the Janus-faced nature of ferroptosis for tumor therapy10.1039/D1NH00506E ↗
10. An injectable hydrogel using an immunomodulating gelator for amplified tumor immunotherapy by blocking the arginase pathway10.1016/j.actbio.2021.01.041 ↗
11. Rational design of a minimalist nanoplatform to maximize immunotherapeutic efficacy: four birds with one stone10.1016/j.jconrel.2020.09.035 ↗
12. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency10.1002/advs.202201734 ↗
13. Engineered nanomaterials for synergistic photo-immunotherapy10.1016/j.biomaterials.2022.121425 ↗
14. Recent advances in hyperthermia therapy-based synergistic immunotherapy10.1002/adma.202004788 ↗
15. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death10.1038/s41467-019-11269-8 ↗
16. Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy10.1038/s41467-019-12771-9 ↗
17. Clinical development and potential of photothermal and photodynamic therapies for cancer
18. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy10.1038/ncomms13193 ↗
19. Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice10.1038/s41467-019-09760-3 ↗
20. Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses10.1126/sciadv.aaz4204 ↗
21. Perfluorocarbon loaded fluorinated covalent organic polymers with effective sonosensitization and tumor hypoxia relief enable synergistic sonodynamic-immunotherapy10.1016/j.biomaterials.2021.121250 ↗
22. Hypoxia as a driver of resistance to immunotherapy10.1016/j.drup.2021.100787 ↗
23. Chemical modulation of glucose metabolism with a fluorinated caco(3) nanoregulator can potentiate radiotherapy by programming antitumor immunity10.1021/acsnano.2c02688 ↗
24. The complex role of tumor-infiltrating macrophages10.1038/s41590-022-01267-2 ↗
25. Tumor-derived retinoic acid regulates intratumoral monocyte differentiation to promote immune suppression10.1016/j.cell.2020.02.042 ↗
26. Macrophages and metabolism in the tumor microenvironment10.1016/j.cmet.2019.06.001 ↗
27. The impact of hypoxia on tumor-associated macrophages10.1172/JCI84427 ↗
28. Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer
29. Ultrasound triggered tumor oxygenation with oxygen-shuttle nanoperfluorocarbon to overcome hypoxia-associated resistance in cancer therapies10.1021/acs.nanolett.6b02365 ↗
30. Perfluorocarbon@Porphyrin nanoparticles for tumor hypoxia relief to enhance photodynamic therapy against liver metastasis of colon cancer10.1021/acsnano.0c05617 ↗
31. Dual mitigation of immunosuppression combined with photothermal inhibition for highly effective primary tumor and metastases therapy10.1016/j.biomaterials.2021.120856 ↗
32. Mitochondria-targeted and ultrasound-responsive nanoparticles for oxygen and nitric oxide codelivery to reverse immunosuppression and enhance sonodynamic therapy for immune activation10.7150/thno.62572 ↗
33. A targeted nanomodulator capable of manipulating tumor microenvironment against metastasis10.1016/j.jconrel.2022.06.022 ↗
34. Mitochondria-targeted and ultrasound-activated nanodroplets for enhanced deep-penetration sonodynamic cancer therapy10.1021/acsami.8b21968 ↗
35. Delivery of folic acid-modified liposomal curcumin for targeted cervical carcinoma therapy10.2147/DDDT.S205787 ↗
36. Thermal-triggered packing of lipophilic NIR dye IR780 in hepatitis B core at critical ionic strength and cargo-host ratio for improved stability and enhanced cancer phototherapy10.1016/j.biomaterials.2021.121035 ↗
37. Dual-depletion of intratumoral lactate and atp with radicals generation for cascade metabolic-chemodynamic therapy10.1002/advs.202102595 ↗
38. Photosensitive nanoparticles combining vascular-independent intratumor distribution and on-demand oxygen-depot delivery for enhanced cancer photodynamic therapy10.1002/smll.201703045 ↗
39. Perfluorooctyl bromide & indocyanine green co-loaded nanoliposomes for enhanced multimodal imaging-guided phototherapy10.1016/j.biomaterials.2018.02.041 ↗
40. Mito-bomb: targeting mitochondria for cancer therapy
41. Photothermal therapy generates a thermal window of immunogenic cell death in neuroblastoma10.1002/smll.201800678 ↗
42. A targeting black phosphorus nanoparticle based immune cells nano-regulator for photodynamic/photothermal and photo-immunotherapy
43. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells, Cell10.1038/cmi.2013.59 ↗
44. Immunogenic cell death and DAMPs in cancer therapy10.1038/nrc3380 ↗
45. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells10.1126/science.1132742 ↗
46. Dual tumor microenvironment remodeling by glucose-contained radical copolymer for MRI-guided photoimmunotherapy10.1002/adma.202107674 ↗
47. Biology of HIF-1alpha10.1038/cdd.2008.12 ↗
48. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha10.1038/nature06905 ↗
49. The role of hypoxia-inducible factor 1 in tumor immune evasion10.1002/med.21771 ↗
50. Phototherapy-induced antitumor immunity: long-term tumor suppression effects via photoinactivation of respiratory chain oxidase-triggered superoxide anion burst10.1089/ars.2015.6334 ↗
51. Bidirectional anisotropic palladium nanozymes reprogram macrophages to enhance collaborative chemodynamic therapy of colorectal cancer10.1016/j.actbio.2022.08.020 ↗
52. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype10.1038/s41467-018-03225-9 ↗
53. Phagocytosis and antigen presentation in dendritic cells10.1111/j.1600-065X.2007.00552.x ↗
54. Coevolution of T-cell receptors with MHC and non-MHC ligands10.1111/imr.12327 ↗